IPF - A NEW HOPE????? WITH ENBREL?????

[Guest guest]

Idiopathic Pulmonary Fibrosis - A New Hope

Introduction

Idiopathic pulmonary fibrosis is a devastating, relentlessly

progressive and lethal disease for which current therapy is minimally

effective. However, several promising anti-fibrotic agents, such as

Enbrel (etanercept), are now in clinical trials, which may lead to

significant improvements in disease survival and create a new high-

value indication, estimated to be worth up to $2 billion annually.

Scope

- Examination of the impact of novel drugs on future treatment,

supported by interviews with key opinion leaders

- Assessment of the trends in epidemiology to 2015, including the

impact of changing demographics and improvements in diagnosis

- Discussion of the challenges to future clinical trial design,

including optimization of patient recruitment and inclusion of novel

endpoints

- Case study forecasting the global sales of Enbrel (etanercept) to

2015

Highlights

Idiopathic pulmonary fibrosis has a five-year survival rate of 20%,

affecting 218,000 people in the global market, of which 60% or

125,000, are diagnosed. The aging of the population, combined with

improvements in diagnosis, will result in a 40% increase in the

diagnosed patient population to 146,000 by 2015.

Novel therapies which demonstrate progression-free survival will be

initiated at diagnosis rather than limited to those patients with

advanced disease, analogous to the treatment of rheumatoid arthritis

or a malignancy, and will create an estimated market of up to $2

billion annually.

Future clinical trials should exclude patients with stable minimal to

moderate and end-stage disease to ensure maximum response to therapy.

The inclusion of acute exacerbation and pharmacoeconomic endpoints is

vital, as is ensuring aggressive treatment with a novel drug that

does not exacerbate pulmonary infections.

FROM MARY LOU

[Guest guest]

Lou, Thanks for the articles...very

interesting!

Especially interesting is the emphasis placed on the money they make if

the drugs work!!!

They aren't very concerned about the patients!!

Z fibriotic NSIP/05

Z 64,

fibriotic NSIP/o5/PA

And “mild”

PH/10/07 and Reynaud’s too!!

No, NSIP was not

self-inflicted…I never smoked!

Potter,

reader,carousel lover and MomMom to

Darah

and Sara

“I’m gonna

be iron like a lion in Zion” Bob Marley

Vinca

Minor-periwinkle is my flower

Lou wrote:

Idiopathic Pulmonary Fibrosis - A New Hope

Introduction

Idiopathic pulmonary fibrosis is a devastating, relentlessly

progressive and lethal disease for which current therapy is minimally

effective. However, several promising anti-fibrotic agents, such as

Enbrel (etanercept), are now in clinical trials, which may lead to

significant improvements in disease survival and create a new high-

value indication, estimated to be worth up to $2 billion annually.

Scope

- Examination of the impact of novel drugs on future treatment,

supported by interviews with key opinion leaders

- Assessment of the trends in epidemiology to 2015, including the

impact of changing demographics and improvements in diagnosis

- Discussion of the challenges to future clinical trial design,

including optimization of patient recruitment and inclusion of novel

endpoints

- Case study forecasting the global sales of Enbrel (etanercept) to

2015

Highlights

Idiopathic pulmonary fibrosis has a five-year survival rate of 20%,

affecting 218,000 people in the global market, of which 60% or

125,000, are diagnosed. The aging of the population, combined with

improvements in diagnosis, will result in a 40% increase in the

diagnosed patient population to 146,000 by 2015.

Novel therapies which demonstrate progression-free survival will

be

initiated at diagnosis rather than limited to those patients with

advanced disease, analogous to the treatment of rheumatoid arthritis

or a malignancy, and will create an estimated market of up to $2

billion annually.

Future clinical trials should exclude patients with stable minimal to

moderate and end-stage disease to ensure maximum response to therapy.

The inclusion of acute exacerbation and pharmacoeconomic endpoints is

vital, as is ensuring aggressive treatment with a novel drug that

does not exacerbate pulmonary infections.

FROM MARY LOU

No virus found in this incoming message.

Checked by AVG - http://www.avg.com

Version: 8.0.138 / Virus Database: 270.5.10/1585 - Release Date: 8/1/2008 6:39 AM